Fundraising Fox

Pulmocide

Founded 2013 · 18 employees on LinkedIn · 14 known investors

Find your way into Pulmocide

108 people in our graph share verified history with the Pulmocide team — schools, employers, funds. One of them is your warm intro.

Deji Sasegbonunlockedknows Kazuhiro Ito · together at Imperial College London (overlapped)
×9knows the team · via Imperial College London
knows the team · via Hokkaido University
knows the team · via Pulmocide

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

BiotechHealthtech

Founders & leadership

Pulmocide was founded in 2013 by Pete Strong, Garth Rapeport, Kazuhiro Ito, and John Murray.

PSPete Strong
Pete StrongCo-founder
GR
Garth RapeportinCo-founder
KI
Kazuhiro ItoinCo-founderKazuhiro Ito spent 13 years at Sankyo Pharmaceutical leading the allergy disease section, followed by 15 years at the National Heart and Lung Institute at Imperial College focusing on respiratory inflammation and infection research. He co-founded RespiVert Ltd in 2007 (acquired by Janssen in 2010) and Pulmocide in 2013, where he leads discovery and clinical development of inhaled anti-infective therapies.
JM
John MurrayinCo-founder
DMDavid Mantus
David MantusinFounder

Investors · 14

Adjuvant CapitalNew York · $10M – $25M
F-Prime CapitalCambridge · $3M – $10M
Jeito CapitalParis
Longwood FundBoston
SR One Capital ManagementRedwood City
SV Health InvestorsBoston · $1M – $20M
Vivo CapitalPalo Alto · $10M – $50M
Johnson & Johnson Innovation – JJDCreportedNew Brunswick
SV Life SciencesreportedBoston

Also in the syndicate · 5

Asahi Kasei PharmaCystic Fibrosis FoundationIP Group plcPictet Alternative AdvisorsleadSR One

Funding

SEC filings, press & company announcements

$52M disclosed across 1 of 2 rounds · 2021–2022

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole - BioSpacebiospace.com · Dec 2022Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Pulmocidepulmocide.com · Dec 2022Pulmocide Receives Investment from the Cystic Fibrosis Foundationfinance.yahoo.com · Dec 2021Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945globenewswire.com · May 2021London-based biotech company Pulmocide raises $30.4m Series Buktech.news · Mar 2017Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financingglobenewswire.com · Mar 2017

Frequently asked questions

What does Pulmocide do?
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.
Who founded Pulmocide?
Pulmocide was founded by Pete Strong, Garth Rapeport, Kazuhiro Ito, John Murray in 2013.
Who are Pulmocide's investors?
Pulmocide's investors include Adjuvant Capital, F-Prime Capital, Jeito Capital, Longwood Fund, SR One Capital Management, SV Health Investors, Vivo Capital, Johnson & Johnson Innovation – JJDC and 1 more.
How much funding has Pulmocide raised?
Pulmocide has disclosed $52M raised across 1 of its 2 known rounds.